Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Int Immunopharmacol ; 81: 106176, 2020 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-32044667

RESUMO

A high salt diet (HSD) is among the most important risk factors for many diseases. One mechanism by which HSD aggravates cerebral ischemic injury is independent of blood pressure changes. The direct role of HSD in inflammation after cerebral ischemia is unclear. In this research, after twenty-one days of being fed a high salt diet, permanent focal ischemia was induced in mice via operation. At 12 h and 1, 3 and 5 days postischemia, the effects of HSD on the lesion volume, microglia polarization, aldose reductase (AR) expression, and inflammatory processes were analyzed. We report that in mice, surplus dietary salt promotes inflammation and increases the activation of classical lipopolysaccharide (LPS)-induced microglia/macrophages (M1). This effect depends on the expression of the AR protein in activated microglia after permanent middle cerebral artery ligation (pMCAL) in HSD mice. The administration of either the AR inhibitor Epalrestat or a p38-neutralizing antibody blocked the polarization of microglia and alleviated stroke injury. In conclusion, HSD promotes polarization in pro-inflammatory M1 microglia by upregulating the expression of the AR protein via p38/MAPK, thereby exacerbating the development of ischemia stroke.


Assuntos
Isquemia Encefálica/metabolismo , Macrófagos/fisiologia , Microglia/fisiologia , Sais/administração & dosagem , Antagonistas de Receptores de Andrógenos/administração & dosagem , Animais , Isquemia Encefálica/patologia , Diferenciação Celular , Citocinas/metabolismo , Ingestão de Alimentos , MAP Quinases Reguladas por Sinal Extracelular/metabolismo , Humanos , Ativação de Macrófagos , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Receptores Androgênicos/metabolismo , Rodanina/administração & dosagem , Rodanina/análogos & derivados , Sais/efeitos adversos , Transdução de Sinais , Células Th1/imunologia , Tiazolidinas/administração & dosagem , Proteínas Quinases p38 Ativadas por Mitógeno/metabolismo
2.
Anticancer Agents Med Chem ; 18(14): 2042-2052, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30062975

RESUMO

BACKGROUND AND OBJECTIVES: Aldose Reductase (AR), a polyol pathway enzyme that mediates diabetic complications is implicated in tumour development and progression. This study was undertaken to determine whether gedunin, a neem limonoid prevents the hallmarks of cancer by inhibiting AR and the associated downstream PI3K/Akt/mTOR/ERK/NF-κB signalling axis in the SCC131 oral cancer cell line. METHODS: The expression of AR and key molecules involved in cell proliferation, apoptosis, autophagy, invasion and angiogenesis was analysed by qRT-PCR, and immunoblotting. ROS generation and cell cycle were analysed by FACS. Alamar blue assay and scratch assay were used to evaluate cell proliferation and migration in the endothelial cell line Eahy926. RESULTS: Gedunin and the AR inhibitor epalrestat inhibited AR expression and ROS generation. Cell cycle arrest at G1/S was associated with cell death by autophagy with subsequent switch over to apoptosis. Furthermore, hypoxia-induced cell migration was inhibited in Eahy926 cells with downregulation of pro-invasive and proangiogenic proteins in SCC131 as well as Eahy926 cells. Co-inactivation of Akt and ERK was coupled with abrogation of IKK/NF-κB signaling. However, the combination of gedunin and epalrestat was more effective than single agents. CONCLUSION: Inhibition of AR-mediated ROS signalling may be a key mechanism by which gedunin and epalrestat exert their anticancer effects. Our results provide compelling evidence that the combination of gedunin and epalrestat modulates expression of key oncogenic signalling kinases and transcription factors primarily by influencing phosphorylation and subcellular localisation. AR inhibitors such as gedunin and epalrestat are novel candidate agents for cancer prevention and therapy.


Assuntos
Aldeído Redutase/antagonistas & inibidores , Azadirachta/química , Carcinoma de Células Escamosas/metabolismo , Inibidores Enzimáticos/farmacologia , Limoninas/farmacologia , Neoplasias Bucais/metabolismo , Oncogenes , Rodanina/análogos & derivados , Transdução de Sinais/efeitos dos fármacos , Tiazolidinas/farmacologia , Carcinoma de Células Escamosas/enzimologia , Carcinoma de Células Escamosas/patologia , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Células Endoteliais/efeitos dos fármacos , Inibidores Enzimáticos/administração & dosagem , Humanos , Limoninas/administração & dosagem , Limoninas/isolamento & purificação , Neoplasias Bucais/enzimologia , Neoplasias Bucais/patologia , NF-kappa B/metabolismo , Fosfatidilinositol 3-Quinases/metabolismo , Proteínas Proto-Oncogênicas c-akt/metabolismo , Espécies Reativas de Oxigênio/metabolismo , Rodanina/administração & dosagem , Rodanina/farmacologia , Tiazolidinas/administração & dosagem
3.
Biomed Res Int ; 2017: 5903105, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28386557

RESUMO

Diabetic nephropathy (DN) is the leading cause of end stage renal disease worldwide. Increased glucose flux into the aldose reductase (AR) pathway during diabetes was reported to exert deleterious effects on the kidney. The objective of this study was to investigate the renoprotective effects of AR inhibition in high glucose milieu in vitro. Rat renal tubular (NRK-52E) cells were exposed to high glucose (30 mM) or normal glucose (5 mM) media for 24 to 48 hours with or without the AR inhibitor epalrestat (1 µM) and assessed for changes in Akt and ERK1/2 signaling, AR expression (using western blotting), and alterations in mitochondrial membrane potential (using JC-1 staining), cell viability (using MTT assay), and cell cycle. Exposure of NRK-52E cells to high glucose media caused acute activation of Akt and ERK pathways and depolarization of mitochondrial membrane at 24 hours. Prolonged high glucose exposure (for 48 hours) induced AR expression and G1 cell cycle arrest and decreased cell viability (84% compared to control) in NRK-52E cells. Coincubation of cells with epalrestat prevented the signaling changes and renal cell injury induced by high glucose. Thus, AR inhibition represents a potential therapeutic strategy to prevent DN.


Assuntos
Aldeído Redutase/antagonistas & inibidores , Diabetes Mellitus Experimental/tratamento farmacológico , Nefropatias Diabéticas/tratamento farmacológico , Rodanina/análogos & derivados , Tiazolidinas/administração & dosagem , Aldeído Redutase/metabolismo , Animais , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Experimental/patologia , Nefropatias Diabéticas/metabolismo , Nefropatias Diabéticas/patologia , Inibidores Enzimáticos/administração & dosagem , Células Epiteliais/efeitos dos fármacos , Células Epiteliais/metabolismo , Células Epiteliais/patologia , Glucose/administração & dosagem , Glucose/metabolismo , Humanos , Rim/efeitos dos fármacos , Rim/metabolismo , Rim/patologia , Túbulos Renais Proximais/efeitos dos fármacos , Túbulos Renais Proximais/enzimologia , Túbulos Renais Proximais/patologia , Sistema de Sinalização das MAP Quinases/efeitos dos fármacos , Proteínas Proto-Oncogênicas c-akt/biossíntese , Ratos , Rodanina/administração & dosagem
4.
Br J Ophthalmol ; 86(8): 860-3, 2002 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-12140204

RESUMO

AIM: While the mechanism in the pathogenesis of diabetic corneal disease is unclear, aldose reductase has been implicated in corneal disease. The effects of an oral aldose reductase inhibitor (ARI) on the ocular surface of diabetic patients after cataract surgery were studied. METHODS: This clinical trial was designed to be randomised, double blinded, and placebo controlled. Pseudophakic patients with diabetes were randomly assigned to treatment with either oral ARI (ONO-2235) (n=12) or placebo (n=9) for 12 weeks. The vital staining of the ocular surface, tear production and clearance, break up time in tears (BUT), corneal and conjunctival sensation, and symptom score before treatments were examined as well as 4, 8, 12 weeks after the administration. Specular microscopic evaluation was also performed. RESULTS: After a 12 week period of oral ARI administration, fluorescein staining scores (from 2.04 (SD 1.12) to 1.46 (1.18); p=0.016), conjunctival sensation (from 1.15 (0.37) to 1.36 (0.31); p=0.0006), and symptom scores (from 5.38 (1.932) to 4.00 (2.07); p=0.0002) recovered significantly. Fluorescein staining of oral ARI administration also decreased compared with placebo (p=0.017). Rose bengal staining, tear clearance, and corneal sensation were improved although this increase was minor. Tear production, BUT, and specular microscopic evaluation of the corneal epithelium and endothelium did not demonstrate a significant change. CONCLUSION: Oral ARI opposes the ocular surface changes caused by diabetes, by recovery of ocular surface sensitivity as demonstrated through an improvement in vital staining.


Assuntos
Aldeído Redutase/antagonistas & inibidores , Extração de Catarata , Diabetes Mellitus/tratamento farmacológico , Inibidores Enzimáticos/administração & dosagem , Epitélio Corneano/efeitos dos fármacos , Rodanina/administração & dosagem , Administração Oral , Idoso , Túnica Conjuntiva/fisiopatologia , Diabetes Mellitus/patologia , Método Duplo-Cego , Epitélio Corneano/patologia , Epitélio Corneano/fisiopatologia , Feminino , Fluoresceína , Corantes Fluorescentes , Humanos , Masculino , Microscopia de Fluorescência , Período Pós-Operatório , Rodanina/análogos & derivados , Rosa Bengala , Sensação , Lágrimas/metabolismo , Tiazolidinas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA